Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationDepreciation ExpenseEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares OutstandingWages, Salaries and Other
Ratios

Sunshine Biopharma (SBFM) Long-Term Debt Repayments (2017 - 2022)

Historic Long-Term Debt Repayments for Sunshine Biopharma (SBFM) over the last 7 years, with Q1 2022 value amounting to $1.9 million.

  • Sunshine Biopharma's Long-Term Debt Repayments rose 385833.33% to $1.9 million in Q1 2022 from the same period last year, while for Dec 2022 it was $1.9 million, marking a year-over-year increase of 29972.65%. This contributed to the annual value of $1.9 million for FY2022, which is 29972.65% up from last year.
  • Per Sunshine Biopharma's latest filing, its Long-Term Debt Repayments stood at $1.9 million for Q1 2022, which was up 385833.33% from $23664.0 recorded in Q4 2021.
  • Over the past 5 years, Sunshine Biopharma's Long-Term Debt Repayments peaked at $1.9 million during Q1 2022, and registered a low of -$767.0 during Q2 2019.
  • Its 5-year average for Long-Term Debt Repayments is $248100.8, with a median of $53767.0 in 2019.
  • Its Long-Term Debt Repayments has fluctuated over the past 5 years, first plummeted by 10502.09% in 2019, then soared by 385833.33% in 2022.
  • Sunshine Biopharma's Long-Term Debt Repayments (Quarter) stood at $48000.0 in 2018, then crashed by 101.6% to -$767.0 in 2019, then soared by 13998.31% to $106600.0 in 2020, then tumbled by 77.8% to $23664.0 in 2021, then skyrocketed by 7929.07% to $1.9 million in 2022.
  • Its Long-Term Debt Repayments was $1.9 million in Q1 2022, compared to $23664.0 in Q4 2021 and $124309.0 in Q3 2021.